Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. [electronic resource]
Producer: 20010329Description: 584-92 p. digitalISSN:- 0732-183X
- Adult
- Aged
- Antineoplastic Agents -- pharmacokinetics
- Endothelial Growth Factors -- blood
- Enzyme Inhibitors -- pharmacokinetics
- Female
- Fibroblast Growth Factor 2 -- blood
- Humans
- Lymphokines -- blood
- Male
- Matrix Metalloproteinase 2 -- blood
- Matrix Metalloproteinase 9 -- blood
- Matrix Metalloproteinase Inhibitors
- Matrix Metalloproteinases -- blood
- Middle Aged
- Neoplasms -- drug therapy
- Statistics, Nonparametric
- Tetracyclines -- pharmacokinetics
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.